ERYTECH Reports First Quarter 2018 Financial Results and Provides Business Update
14 mai 2018 16h30 HE
|
Erytech Pharma S.A.
Finalized Phase 3 trial design for eryaspase in second line pancreatic cancer; on track for expected start of patient enrollment in Q3Selected triple-negative breast cancer as the next solid tumor...
Biothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)
23 févr. 2017 09h00 HE
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that dosing has been initiated in a Phase 2 clinical trial evaluating Biothera’s Imprime PGG in...